A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study - PubMed (original) (raw)

A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study

Carolyn W Zhu et al. Alzheimers Dement (N Y). 2018.

Abstract

Introduction: Human studies on low-dose resveratrol are scarce. This study aims to evaluate the safety, tolerability, and efficacy of an oral preparation of resveratrol, glucose, and malate (RGM) in slowing the progression of Alzheimer's disease (AD).

Methods: Thirty-nine subjects with mild to moderate AD who were free of life-threatening disease and who did not have contraindications to the use of the study product were screened. Progression of AD was measured by change in the cognitive portion of the Alzheimer's Disease Assessment Scale-cognitive subscale. Secondary outcomes included Clinician's Global Impression of Change, Mini-Mental State Examination, Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale, and Neuropsychiatric Inventory. 15 mL of the following preparation per dose, i.e., 5 g dextrose, 5 g malate, and 5 mg resveratrol, or matching placebo was ingested with an 8 oz glass of commercial unsweetened grape juice twice a day for 1 year. Group differences in the rate of change in the outcome measures were examined using generalized estimating equations.

Results: The treatment and control groups were similar on all of the screening variables. At 12 months, change scores on Alzheimer's Disease Assessment Scale-cognitive subscale, Mini-Mental State Examination, Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale, or Neuropsychiatric Inventory all showed less deterioration in the treatment than the control group; however, none of the change scores reached statistical significance. The most common AE were falls, all in the control group. None of the falls were deemed to be study related.

Conclusion: Low-dose oral resveratrol is safe and well tolerated. Interpretation of the effects on clinical outcomes trajectories remains uncertain. A larger study is required to determine whether low-dose resveratrol may be beneficial.

Trial registration: ClinicalTrials.gov (NCT00678431), Registered 05/15/2008.

Keywords: Double-blind methods; Drug therapy; Efficacy; Resveratrol; Safety.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Consort Diagram and Disposition by Treatment Group.

Fig. 2

Fig. 2

Mean change scores from baseline at each follow-up visit in treatment and placebo groups. Vertical bars represent standard deviation. Blue arrow indicates direction of improvement. (A) Positive change scores in ADAS-cog indicate worsening impairment from baseline. (B) Positive change scores in ADCS-ADL indicate improvement from baseline. (C) Positive change scores in MMSE indicate improvement from baseline. (D) Positive change scores in NPI indicate worsening impairment from baseline. Abbreviations: ADAS-cog, Alzheimer's Disease Assessment Scale–cognitive subscale; MMSE, Mini–Mental State Examination; ADCS-ADL, Alzheimer's Disease Cooperative Study–Activities of Daily Living Scale; NPI, Neuropsychiatric Inventory.

Similar articles

Cited by

References

    1. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci. 2004;5:677–685. - PubMed
    1. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius H.J. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006;63:49–54. - PubMed
    1. Reisberg B., Shao Y., Golomb J., Monteiro I., Torossian C., Boksay I. Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial. Dement Geriatr Cogn Disord. 2017;43:100–117. - PMC - PubMed
    1. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547–554. - PubMed
    1. Cummings J., Lee G., Ritter A., Zhong K. Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement (N Y) 2018;4:195–214. - PMC - PubMed

LinkOut - more resources